Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of three antidepressant medications—sertraline, paroxetine, and venlafaxine. Sertraline and paroxetine are selective serotonin reuptake inhibitors (SSRIs), while venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI). All three drugs act primarily by increasing the levels of serotonin in the brain, with venlafaxine also increasing norepinephrine. These agents are individually approved for major depressive disorder and other psychiatric conditions such as anxiety disorders and post-traumatic stress disorder (PTSD)[1][2][7]. The combination of multiple antidepressants is sometimes considered in treatment-resistant depression but carries an increased risk of adverse effects, including serotonin syndrome[3][4][5]. There is limited evidence supporting the simultaneous use of all three together; most clinical experience involves combining one SSRI with an SNRI or other agent when monotherapy fails[3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sertraline + paroxetine + venlafaxine.